Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Identifieur interne : 002009 ( Pmc/Corpus ); précédent : 002008; suivant : 002010Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Auteurs : Andrea Decensi ; Zhuoxin Sun ; Aliana Guerrieri-Gonzaga ; Beat Thürlimann ; Christina Mcintosh ; Carlo Tondini ; Alain Monnier ; Mario Campone ; Marc Debled ; Astrid Schönenberger ; Khalil Zaman ; Harriet Johansson ; Karen N. Price ; Richard D. Gelber ; Aron Goldhirsch ; Alan S. Coates ; Stefan AebiSource :
- Breast cancer research and treatment [ 0167-6806 ] ; 2014.
Abstract
To determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); 2-years L, 3-years T (LT).
Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after three (n=150), four (n=200), and five years (n=74) from randomization, and one year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin and bone alkaline phosphatase with T-scores were assessed.
At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score differences were significant for T vs. L or TL, and L vs. LT. The 5-year prevalence of spine and femur osteoporosis was highest on TL (14.5%, 7.1%) then L (4.3%, 5.1%), LT (4.2%, 1.4%) and T (4%, 0). C-telopeptide and osteocalcin were significantly associated with T-scores.
While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.
clinicaltrials.gov NCT00369850
Url:
DOI: 10.1007/s10549-014-2849-2
PubMed: 24487691
PubMed Central: 3982877
Links to Exploration step
PMC:3982877Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences</title><author><name sortKey="Decensi, Andrea" sort="Decensi, Andrea" uniqKey="Decensi A" first="Andrea" last="Decensi">Andrea Decensi</name><affiliation><nlm:aff id="A1">Division of Medical Oncology, E.O. Ospedali Galliera, Genoa, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Sun, Zhuoxin" sort="Sun, Zhuoxin" uniqKey="Sun Z" first="Zhuoxin" last="Sun">Zhuoxin Sun</name><affiliation><nlm:aff id="A2">International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public health, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Guerrieri Gonzaga, Aliana" sort="Guerrieri Gonzaga, Aliana" uniqKey="Guerrieri Gonzaga A" first="Aliana" last="Guerrieri-Gonzaga">Aliana Guerrieri-Gonzaga</name><affiliation><nlm:aff id="A3">Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name><affiliation><nlm:aff id="A4">Breast Center, Kantonsspital, St. Gallen and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Mcintosh, Christina" sort="Mcintosh, Christina" uniqKey="Mcintosh C" first="Christina" last="Mcintosh">Christina Mcintosh</name><affiliation><nlm:aff id="A5">Department of Biostatistics, Harvard School of Public Health, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Tondini, Carlo" sort="Tondini, Carlo" uniqKey="Tondini C" first="Carlo" last="Tondini">Carlo Tondini</name><affiliation><nlm:aff id="A6">Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy</nlm:aff></affiliation></author><author><name sortKey="Monnier, Alain" sort="Monnier, Alain" uniqKey="Monnier A" first="Alain" last="Monnier">Alain Monnier</name><affiliation><nlm:aff id="A7">University of Franche Comté, IRMA Team-UMR 6249 CNRS, Montbèliard, France</nlm:aff></affiliation></author><author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name><affiliation><nlm:aff id="A8">Department of Medical Oncology, Institut de Cancerologie de l’OUEST, Saint-Herblain-Nantes, France</nlm:aff></affiliation></author><author><name sortKey="Debled, Marc" sort="Debled, Marc" uniqKey="Debled M" first="Marc" last="Debled">Marc Debled</name><affiliation><nlm:aff id="A9">Department of Medicine, Institut Bergonié, Bordeaux, France</nlm:aff></affiliation></author><author><name sortKey="Schonenberger, Astrid" sort="Schonenberger, Astrid" uniqKey="Schonenberger A" first="Astrid" last="Schönenberger">Astrid Schönenberger</name><affiliation><nlm:aff id="A10">Spital Langenthal SRO AG, Langenthal, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Zaman, Khalil" sort="Zaman, Khalil" uniqKey="Zaman K" first="Khalil" last="Zaman">Khalil Zaman</name><affiliation><nlm:aff id="A11">Breast Center, University Hospital CHUV, Lausanne, Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Johansson, Harriet" sort="Johansson, Harriet" uniqKey="Johansson H" first="Harriet" last="Johansson">Harriet Johansson</name><affiliation><nlm:aff id="A12">Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation><nlm:aff id="A13">International Breast Cancer Study Group (IBCSG) Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation><nlm:aff id="A14">International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation><nlm:aff id="A15">Division of Medical Oncology, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation><nlm:aff id="A16">International Breast Cancer Study Group, Bern, Switzerland and University of Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Aebi, Stefan" sort="Aebi, Stefan" uniqKey="Aebi S" first="Stefan" last="Aebi">Stefan Aebi</name><affiliation><nlm:aff id="A17">Luzerner Kantonsspital, Lucerne, University of Bern, and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24487691</idno><idno type="pmc">3982877</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982877</idno><idno type="RBID">PMC:3982877</idno><idno type="doi">10.1007/s10549-014-2849-2</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">002009</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002009</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences</title><author><name sortKey="Decensi, Andrea" sort="Decensi, Andrea" uniqKey="Decensi A" first="Andrea" last="Decensi">Andrea Decensi</name><affiliation><nlm:aff id="A1">Division of Medical Oncology, E.O. Ospedali Galliera, Genoa, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Sun, Zhuoxin" sort="Sun, Zhuoxin" uniqKey="Sun Z" first="Zhuoxin" last="Sun">Zhuoxin Sun</name><affiliation><nlm:aff id="A2">International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public health, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Guerrieri Gonzaga, Aliana" sort="Guerrieri Gonzaga, Aliana" uniqKey="Guerrieri Gonzaga A" first="Aliana" last="Guerrieri-Gonzaga">Aliana Guerrieri-Gonzaga</name><affiliation><nlm:aff id="A3">Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name><affiliation><nlm:aff id="A4">Breast Center, Kantonsspital, St. Gallen and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Mcintosh, Christina" sort="Mcintosh, Christina" uniqKey="Mcintosh C" first="Christina" last="Mcintosh">Christina Mcintosh</name><affiliation><nlm:aff id="A5">Department of Biostatistics, Harvard School of Public Health, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Tondini, Carlo" sort="Tondini, Carlo" uniqKey="Tondini C" first="Carlo" last="Tondini">Carlo Tondini</name><affiliation><nlm:aff id="A6">Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy</nlm:aff></affiliation></author><author><name sortKey="Monnier, Alain" sort="Monnier, Alain" uniqKey="Monnier A" first="Alain" last="Monnier">Alain Monnier</name><affiliation><nlm:aff id="A7">University of Franche Comté, IRMA Team-UMR 6249 CNRS, Montbèliard, France</nlm:aff></affiliation></author><author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name><affiliation><nlm:aff id="A8">Department of Medical Oncology, Institut de Cancerologie de l’OUEST, Saint-Herblain-Nantes, France</nlm:aff></affiliation></author><author><name sortKey="Debled, Marc" sort="Debled, Marc" uniqKey="Debled M" first="Marc" last="Debled">Marc Debled</name><affiliation><nlm:aff id="A9">Department of Medicine, Institut Bergonié, Bordeaux, France</nlm:aff></affiliation></author><author><name sortKey="Schonenberger, Astrid" sort="Schonenberger, Astrid" uniqKey="Schonenberger A" first="Astrid" last="Schönenberger">Astrid Schönenberger</name><affiliation><nlm:aff id="A10">Spital Langenthal SRO AG, Langenthal, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Zaman, Khalil" sort="Zaman, Khalil" uniqKey="Zaman K" first="Khalil" last="Zaman">Khalil Zaman</name><affiliation><nlm:aff id="A11">Breast Center, University Hospital CHUV, Lausanne, Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Johansson, Harriet" sort="Johansson, Harriet" uniqKey="Johansson H" first="Harriet" last="Johansson">Harriet Johansson</name><affiliation><nlm:aff id="A12">Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation><nlm:aff id="A13">International Breast Cancer Study Group (IBCSG) Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation><nlm:aff id="A14">International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA</nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation><nlm:aff id="A15">Division of Medical Oncology, European Institute of Oncology, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation><nlm:aff id="A16">International Breast Cancer Study Group, Bern, Switzerland and University of Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Aebi, Stefan" sort="Aebi, Stefan" uniqKey="Aebi S" first="Stefan" last="Aebi">Stefan Aebi</name><affiliation><nlm:aff id="A17">Luzerner Kantonsspital, Lucerne, University of Bern, and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</nlm:aff></affiliation></author></analytic><series><title level="j">Breast cancer research and treatment</title><idno type="ISSN">0167-6806</idno><idno type="eISSN">1573-7217</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose</title><p id="P1">To determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); 2-years L, 3-years T (LT).</p></sec><sec id="S2"><title>Methods</title><p id="P2">Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after three (n=150), four (n=200), and five years (n=74) from randomization, and one year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin and bone alkaline phosphatase with T-scores were assessed.</p></sec><sec id="S3"><title>Results</title><p id="P3">At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score differences were significant for T vs. L or TL, and L vs. LT. The 5-year prevalence of spine and femur osteoporosis was highest on TL (14.5%, 7.1%) then L (4.3%, 5.1%), LT (4.2%, 1.4%) and T (4%, 0). C-telopeptide and osteocalcin were significantly associated with T-scores.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.</p></sec><sec id="S5"><title>Trial registration</title><p id="P5">clinicaltrials.gov NCT00369850</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8111104</journal-id><journal-id journal-id-type="pubmed-jr-id">1254</journal-id><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res. Treat.</journal-id><journal-title-group><journal-title>Breast cancer research and treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn></journal-meta><article-meta><article-id pub-id-type="pmid">24487691</article-id><article-id pub-id-type="pmc">3982877</article-id><article-id pub-id-type="doi">10.1007/s10549-014-2849-2</article-id><article-id pub-id-type="manuscript">NIHMS562557</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>DeCensi</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><email>andrea.decensi@galliera.it</email></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Zhuoxin</given-names></name><xref ref-type="aff" rid="A2">2</xref><email>zhuxoin@jimmy.harvard.edu</email></contrib><contrib contrib-type="author"><name><surname>Guerrieri-Gonzaga</surname><given-names>Aliana</given-names></name><xref ref-type="aff" rid="A3">3</xref><email>aliana.guerrieri-gonzaga@ieo.it</email></contrib><contrib contrib-type="author"><name><surname>Thürlimann</surname><given-names>Beat</given-names></name><xref ref-type="aff" rid="A4">4</xref><email>beat.thuerlimann@kssg.ch</email></contrib><contrib contrib-type="author"><name><surname>McIntosh</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="A5">5</xref><email>cmm862@mail.harvard.edu</email></contrib><contrib contrib-type="author"><name><surname>Tondini</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="A6">6</xref><email>carlo.tondini@ospedaliriuniti.bergamo.it</email></contrib><contrib contrib-type="author"><name><surname>Monnier</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="A7">7</xref><email>dramonnier@orange.fr</email></contrib><contrib contrib-type="author"><name><surname>Campone</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="A8">8</xref><email>Mario.Campone@ico.unicancer.fr</email></contrib><contrib contrib-type="author"><name><surname>Debled</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="A9">9</xref><email>m.debled@bordeaux.unicancer.fr</email></contrib><contrib contrib-type="author"><name><surname>Schönenberger</surname><given-names>Astrid</given-names></name><xref ref-type="aff" rid="A10">10</xref><email>a.schoenenberger@sro.ch</email></contrib><contrib contrib-type="author"><name><surname>Zaman</surname><given-names>Khalil</given-names></name><xref ref-type="aff" rid="A11">11</xref><email>Khalil.Zaman@chuv.ch</email></contrib><contrib contrib-type="author"><name><surname>Johansson</surname><given-names>Harriet</given-names></name><xref ref-type="aff" rid="A12">12</xref><email>harriet.johansson@ieo.it</email></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>Karen N.</given-names></name><xref ref-type="aff" rid="A13">13</xref><email>price@jimmy.harvard.edu</email></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>Richard D.</given-names></name><xref ref-type="aff" rid="A14">14</xref><email>gelber@jimmy.harvard.edu</email></contrib><contrib contrib-type="author"><name><surname>Goldhirsch</surname><given-names>Aron</given-names></name><xref ref-type="aff" rid="A15">15</xref><email>aron.goldhirsch@ibcsg.org</email></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>Alan S.</given-names></name><xref ref-type="aff" rid="A16">16</xref><email>alan.coates@ibcsg.org</email></contrib><contrib contrib-type="author"><name><surname>Aebi</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="A17">17</xref><email>stefan.aebi@onkologie.ch</email></contrib><on-behalf-of>for the BIG 1-98 Collaborative and International Breast Cancer Study Groups</on-behalf-of></contrib-group><aff id="A1"><label>1</label>Division of Medical Oncology, E.O. Ospedali Galliera, Genoa, Italy</aff><aff id="A2"><label>2</label>International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public health, Boston, MA</aff><aff id="A3"><label>3</label>Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</aff><aff id="A4"><label>4</label>Breast Center, Kantonsspital, St. Gallen and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</aff><aff id="A5"><label>5</label>Department of Biostatistics, Harvard School of Public Health, Boston, MA</aff><aff id="A6"><label>6</label>Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy</aff><aff id="A7"><label>7</label>University of Franche Comté, IRMA Team-UMR 6249 CNRS, Montbèliard, France</aff><aff id="A8"><label>8</label>Department of Medical Oncology, Institut de Cancerologie de l’OUEST, Saint-Herblain-Nantes, France</aff><aff id="A9"><label>9</label>Department of Medicine, Institut Bergonié, Bordeaux, France</aff><aff id="A10"><label>10</label>Spital Langenthal SRO AG, Langenthal, Switzerland</aff><aff id="A11"><label>11</label>Breast Center, University Hospital CHUV, Lausanne, Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</aff><aff id="A12"><label>12</label>Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy</aff><aff id="A13"><label>13</label>International Breast Cancer Study Group (IBCSG) Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA</aff><aff id="A14"><label>14</label>International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA</aff><aff id="A15"><label>15</label>Division of Medical Oncology, European Institute of Oncology, Milan, Italy</aff><aff id="A16"><label>16</label>International Breast Cancer Study Group, Bern, Switzerland and University of Sydney, Australia</aff><aff id="A17"><label>17</label>Luzerner Kantonsspital, Lucerne, University of Bern, and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland</aff><author-notes><corresp id="FN1">Corresponding author prior to publication: Karen N Price, IBCSG Statistical Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, Mailstop CLS-11007, tel: +1 617-632-2459; fax: +1 617-632-2444; <email>price@jimmy.harvard.edu</email></corresp><corresp id="FN2">Corresponding author after publication: Andrea DeCensi, MD, Division of Medical Oncology, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy, tel.: +39-0105634501; fax: +39-01057481090; <email>andrea.decensi@galliera.it</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>31</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>01</day><month>2</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2015</year></pub-date><volume>144</volume><issue>2</issue><fpage>321</fpage><lpage>329</lpage><pmc-comment>elocation-id from pubmed: 10.1007/s10549-014-2849-2</pmc-comment>
<abstract><sec id="S1"><title>Purpose</title><p id="P1">To determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); 2-years L, 3-years T (LT).</p></sec><sec id="S2"><title>Methods</title><p id="P2">Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after three (n=150), four (n=200), and five years (n=74) from randomization, and one year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin and bone alkaline phosphatase with T-scores were assessed.</p></sec><sec id="S3"><title>Results</title><p id="P3">At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score differences were significant for T vs. L or TL, and L vs. LT. The 5-year prevalence of spine and femur osteoporosis was highest on TL (14.5%, 7.1%) then L (4.3%, 5.1%), LT (4.2%, 1.4%) and T (4%, 0). C-telopeptide and osteocalcin were significantly associated with T-scores.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.</p></sec><sec id="S5"><title>Trial registration</title><p id="P5">clinicaltrials.gov NCT00369850</p></sec></abstract><kwd-group><kwd>breast cancer</kwd><kwd>adjuvant drug therapy</kwd><kwd>aromatase inhibitor</kwd><kwd>bone density</kwd><kwd>bone turnover</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002009 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002009 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3982877
|texte= Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:24487691" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |